us and joining our the of we going quarter you first our today results We Good XXXX afternoon, as appreciate everybody. forward. discuss outlook for
by detail, I'd As like and hope it takeaways three discussion highlights, walk and key start commercial saying will you today. the that through some usual, through are open with Susan in our guidance to Q&A. the business I'll I there up walk then away of more financials then come and to from and there we'll
growth enable of market. reaching instrument rapidly base shipments. install of record executing our the core data our First, the more IIe another us of install achieving II on expanding Sequel in base as will evidenced we and This systems objective are by HiFi quarter
and short Second, our on progress long-read excellent we of next-generation making are sequencers.
for PacBio without track on the most a commercial based also financial we commercialization estimates, mid positive next on is Our operating on short-read will our cash accurate until on throughput the And capital. third, cash the to achieving based this continue platform. shipment instrument balance and using development -- need raise and first sequencers. current long-read And our milestones believe intend to be company's position our the half plans year. strong in internal reach sheet, world's and to additional of fund our in investments the of we SBB development next-gen We're flows we short-read is towards the
volatility today, equity puts markets the and unique With position. the in a desirable this us in
to discuss the through results walk track let's our how our XXXX on team on is Now, execute and QX plan.
solid The first of our in the the increase revenue quarter XX% of year. guidance and last $XX.X a million, range upper to quarter of with to start year a the compared was end first
touch in on full to Given million that million $XXX revenues first our quarter, revenue the will $XXX Susan expect later. to growth. XXXX we approximately continue at or XX% XX% year to for
revenue -- call, on lower the customers. quarter operations COVID-XX-related we our with that team's internal interact was to to our first ability due discussed act As our headwinds last customer disrupted sequentially and
first purchases. value which II Despite one-third and of that the exacerbated headwinds, some to XX continues with team typical placements pleased PacBio delayed IIe instrument II quarter placements. seasonality were of underscore sequencing. This these quarter quarter IIe is another capital customers, I'm the record instrument over and and expanding Additionally, the was proposition to HiFi third Sequel Sequel consecutive by new headwinds record delivered to macroeconomic share
plant applications health to customer and from reproductive editing other New animal, to and areas. gene range
improved significant we've shipped two years in investment sales are momentum aggressive We IIe in than And enhancements. first driven platform the placing the by our started XXXX. since We launch. gaining then and early commercial more systems and Sequel II in of product increased our productivity presence,
will each and growth revenue investment step may new believe term. rep expand territory. to medium amounts in We time new base Our of are per our reps in sales spending opportunities. Salesforce sales in this a pipeline short-term, drive is prospecting expanding lead lower grows, consumable as sales the the our over and sustainable is as the revenue significant per a building This temporary, in it rep for install crucial
as consumables instruments, mix gains product than Additionally, benefit and will our we carry gross higher from also gross changes. margin margins as generally
sales productivity, we've revenue one Our rep sales velocity made progress is sales for and improving excellent the in drive to only metric our cycle. of
continued quarter we For metric the example, That our first to nearly instrument last XX% quarter. over sales current sales. turns with quarter, of shipments the discussed of our shipments quarter in from turned instrument instrument trend productivity, all within our in as understand were quarter the
of to Institute in investment install Sequel enhancements pleased are and to the Sequel the PacBio's we Broad delivered world. and breath platform, we IIes to to couldn't in XX of the quarter. largest IIe II sequencing HiFi the genome customer Their further initiatives a we first month the that To range whole share the Additionally, more expand addressable and systems research applications, with positions with pleased in of base transcriptome them additional technology IIe Sequel significant be launched we the last address reception.
with or processes sequencing Lab library for significantly on epigenetics. Our and DNA just added and applications new of cell. workflow recombinant can of products runs steps to believe in for Other insertion processes. even And long-read particularly and analysis for a genome DNA the fail sequencing and with a now separating library analysis the simplified characterizes sequencing require library epigenome and allow in explain adds at do impact lower adeno-associated from don't offering RAAV, more in from and field separation, scalable methylation special sample also and the address genome single approaches methylation. sequencing new customers sequencing to whole the by the and and the special whole deletion We they enable with one need like just and support short-reads, microgram methylation measuring differences protocol two instrument genome to technologies run on virus, will in throughput. prep requires one HiFi detection separate therapy for genome technicians as sequence no genetic the detect in a Epigenetic cost, the genome single DNA HiFi and match and a gene genome. both run, trades shift variant now instrument cost research complex directly time. DNA HiFi phasing epigenome, higher DNA large smart epigenome methylation preparation per sequencing which The for to alleles input, to accuracy, much are simultaneously and sequencing differences our have sequencing sequencing go whole
sequencing with instrument offering methylation effort. additional no directly Our from DNA the provides
higher four than with further transcriptomic that drivers the collaboration its into how increase variance. coding, to offering to genomic our and existing new improve Children’s we're and rare how we expanding and power sequencing transcriptomic Iso-Seq times research. rare exploring this in our They've output Isoform methylation Mercy disease study is expect City use methylation include will use throughput capabilities transforming these associated a PacBio structural with a multi-omic epigenetic for forward of new two more workflows of Iso-Seq understand to the HiFi dramatically case has us We and we strengthen to demonstrated and variants research short-read uncovered are in look examples HiFi. later adding already Kansas Our company. its addition year sequencing, believe features kit of will like their underlying
in a the We're And AAV AAV over short-reads related to novel demonstrate quality gene success add collaborations of working applications. control due therapies at therapy AAV in play are our a which several genomes HiFi research therapy an with now less miss and for exciting offer impact pleased design, to manufacturing products. full also with accuracy and analysis and goal This across protocol, critical HiFi first dozen accuracy. important visibility AAV in to have sequencing qPCR new the complete present to High We our solution ability continue critical long-read clinical very our an be companies we research. believe may because its over working of to gene is is We sequence of therapy list could discovery, collaborators role that therapy vector to can quarter. can the utility vector accurate growing technology gene AAV on research. gene and AAV-based research vector area high rapidly negatively today. XXX the changes vector sequence, customer's length important for
sequencing to reads genomes. instruments example PacBio and AAV developing to delivered are two tailored reference of quarters, customer de and highly needs. several pipeline. novo research long sales HiFi accurate new that past the go-to to a to is their eight yet customers value how the specific PacBio our been new have animal and feature technology building bring due and application on working more end-to-end in plant has This solutions complex we've assembly long in we our genomes Over another
to available production more broadly are sequencing agricultural XXXX. app sometime pipelines. HiFi We end-to-end HiFi research order that protocols new will plant, to resource accuracy methods to high are to throughput as efficient, further critical and new to test length broad in genomes adoption required. enable commercial However, made higher these Corteva seed the for seed we be be and development, working and assemble. microbial and of crop community that product to their harder is development of to with protection are develop sequence agriculture, complex To throughput and anticipate sequencing new in these and end, The workflows tend Agriscience in
amplification DNA; I'd molecular moment bioinformatics to three critical -- I'd so and integrity, to like take a preparation of native of Moving advantages to describe simpler absence sample in workflow. on, using steps, like
native extracted of structural lead to from metagenome well sequences synthetic novo approaches, the phasing, detection. to be are communities, phasing, and cells DNA epigenetic results are can directly genome and molecules as having continuity assemblies, in sequencing, information as longer much to submitted longer continue that haplotype fragment and the improves the compared greater because First, variant DNA de
DNA potentially regions and inaccurate procedures Synthetic sequencing DNA molecular risk DNA and that require methylation and studies by long artifacts limitations Sequencing due molecules, completeness. genomes sequencing our to not confounding effort. the sequence native epigenetic application to molecules to reads polyploid significantly steps, with upfront as of definition with aspects variants therefore information. without enables short PacBio the without end. long genome, which the complicated these resulting reconstructs. biases, structural reads other sequencing, require simplifies into the resolving amplification information unaltered of subtraction or introduce by other does information. are native PacBio native genomes back Thus, recorrection can look be any loss both biology accesses bioinformatic these coverage molecules earlier, phased third, consensus sample steps sequencer at resolving simultaneously library prone can of therefore use synthetic control PacBio itself, to whole computations native molecules in at reads genome complete difficult additional overcome to from artifacts. workflow native or and diploid the procedures, sequencing alleles result I long-read provides thereby in all Further, not which fully the better can enormity, not genetic greater of oversampling do the other Second, steps, long preparation from genome with considered bioinformatics And biases provide and -- fragmentation errors, HiFi reassembly and samples. technology and of from in described achieving
the native ever applications. believe provide telomere-to-telomere complete attempts accurate, reads We synthetic highlighted X% time have eventually more seen most landmark publications time decade, with contiguous long-read Nothing continue numerous and has will genome. at which of over all the sequencing information to limitations the were We and the final approaches, epigenomic which and completed abandoned. sequencing long past the from the and increasing whole short-read than genomic the of again, consortium,
Something of in years despite improvements short-read sequencing to been AI. and do that unable had informatics
from sequenced and given get insufficient I the genomes the the FDA by few with short-read and Cost the resource edge have are past launch sequencing just over question data today. being and ubiquitous the ago of years as of winner in and why incomplete throughput precision long-read But then technologies defacto isn't Why accuracy the the biomolecular evidenced historically sequencing decade. sequencing, a PacBio short-read the all accuracy and association HiFi HiFi technology? with So, made became still often at facilities. leader the
genetic of broader historical outside of in improvements research sequencing the the increased areas. in health. applications, human clinical of adoption of collaborations Our now growing and discuss editing We've in oncology, adoption its handful and we enabled customers gene much disease as in have HiFi accuracy long-read research reproductive list seen conducting niche
throughput We next-generation barriers expect HiFi HiFi. will large and adoption the two mark inflection of of long-read genome sequencing the and equipped whole sequencers using remaining with our cost of overcome point scale adoption,
do be we on the Moving sequencer. will launch track accurate short onto We reads. to believe most what remain short-read
sequencer this high HiFi address growth in market where be expect may We sequencing genomics other areas not the will necessary.
give the address force world-class PacBio's address in to our transformative several this needs. over market. fit It to for our as the the technology next we application way years. best not entire these deliver As right chemistry is strategy, built right ability that We team part see products one develop confidence in along that of aim the we to have me the customer's to sequencing develop the instrument and with and
have I on environment, requires our extremely substantial as $X the market that we until the intend investment. access positive And And flow, cash the today's are cash we have to without operating earlier commercialization investments mentioned, to need fortunate we However, on using mission markets. and capital to in currently financing in and reach nearly we billion fund cash our delivering development programs and uncertain balance current sheet on balance sheet. our
moment take you to like our with on I'd update collaboration a Invitae. Finally, to
the and we As platform partnered very well clinical of to create high each a there an HiFi new throughput be you is thousands tens at of for sequencer may to development with The potential of sequencing enthusiasm adopting scale ultra recall, this year. setting. capable going sequencing whole great have of genomes Invitae in continues of
the of to be such to longer consumables collaboration. given and with to no the we payments expected capital pricing and us, our In and platform Invitae that amend more exchange, difficult phase research are the increased and agreement related during the market of make Invitae asked our in the will development be environment planning However, Invitae's will line price.
collaboration will The other of the aspects continue.
project. aspects example, continue will of their assist we Invitae in other development pipelines the workflows, to resources the scaled and For bioinformatics to of expect internal leverage
of believe Invitae result a large will users on As high level of more field that our with system. scale other playing ultra a amendment, be throughput this we
second want compete timelines, the the not reiterate amendment and does to I that, reflect the result in environment results is hand the this more -- that the macroeconomic call proposed to amendment of to expect I'll company's development funding during quarter. the complete either financial performance specifications. or our Susan to for other With collaboration, enthusiasm date about the to product detail. Susan? off talk We
